Abstract:
Provided are compounds which generally have a triketone structure. Examples of the compounds include derivatives of 1,3-cyclohexanedione, such as: 1,3-cyclohexanedione, 2-propanoyl-5-cyclohexyl-; 1,3-cyclohexanedione, 2-propanoyl-5-[4-fluorophenyl]-; 1,3-cyclohexanedione, 2-acetyl-5-[thien-2-yl]-; 1,3-cyclohexanedione, 2-acetyl-5 -butyl-; and 1,3-cyclohexanedione, 2-propanoyl-5-[bicyclo[2.2.1]hept-2-en-5-yl]-. The compounds can be used to alter the lifespan of eukaryotic organisms and treat inflammation.
Abstract:
Substituted cyclohexanedione derivatives of general formula (I), and their salts, enamine and analogous derivatives, acylates, sulfonates, carbamates, and ether derivatives, each having herbicidal and plant growth regulating actions, wherein R represents lower alkyl or optionally substituted phenyl, aralkyl or heterocyclic group; Y represents straight-chain or branched lower alkylene; m is 0 or 1; R represents hydrogen or straight-chain or branched lower alkyl; R groups may be the same or different from one another and each represents halogen, cyano, alkyl, haloalkyl, cyanoalkyl, alkoxycarbonyl, or optionally substituted phenyl; n is 0, 1, 2, 3, 4 or 5; Z represents W or OR ; Z represents SR or OR , or alternatively Z and Z are combined together to represent oxygen, CR R or N-r, wherein R represents hydrogen or alkyl, R represents hydrogen, alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, or optionally substituted phenyl, and r represents hydrogen, alkyl, alkoxy, haloalkoxy, alkenyloxy, or haloalkenyloxy; W represents halogen, SR or OR ; R represents optionally substituted phenyl or heterocyclic group; R and R each represents alkyl or optionally substituted phenyl or heterocyclic group; and R represents alkyl or two R groups are combined together to represent alkylene.
Abstract translation:通式(I)的取代的环己二酮衍生物及其盐,烯胺和类似衍生物,酰化物,磺酸盐,氨基甲酸盐和醚衍生物,各自具有除草和植物生长调节作用,其中R 1表示低级烷基或任选取代的苯基 ,芳烷基或杂环基; Y表示直链或支链低级亚烷基; m为0或1; R 2表示氢或直链或支链的低级烷基; R 3基团可以彼此相同或不同,并且各自表示卤素,氰基,烷基,卤代烷基,氰基烷基,烷氧基羰基或任选取代的苯基; n为0,1,2,3,4或5; Z 1表示W或OR 9; Z 2表示SR 6或OR 9,或者Z 1和Z 2组合在一起代表氧,CR 4 R 5或Nr,其中R 4表示 氢或烷基,R 5表示氢,烷基,烯基,烷氧基烷基,烷硫基烷基或任选取代的苯基,r表示氢,烷基,烷氧基,卤代烷氧基,烯氧基或卤代烯氧基。 W表示卤素,SR 7或OR 8; R 6表示任选取代的苯基或杂环基; R 7和R 8各自表示烷基或任选取代的苯基或杂环基; R 9代表烷基或两个R 9基团组合在一起代表亚烷基。
Abstract:
The invention relates to novel mixtures consisting of at least two substances, one substance being used as a matrix material and the other as a material which is capable of emission and contains at least one element having an atomic number larger than 20. The invention also relates to the use of said mixtures in organic electronic components such as electroluminescence elements and displays.
Abstract:
Apoptosis inhibitors containing as the active ingredient compounds represented by general formula (I) or salts thereof, wherein W1 represents -O-, -CH2-, etc.; W2 represents -CH2-, etc.; W3 represents -O-, -CH2-, etc.; X represents CH, C , etc.; and A represents formula ( alpha ) wherein W4 represents -O-, -CH2-, etc.; W5 represents -CH2-, etc.; and W6 represents -O-, -CH2-, etc. These apoptosis inhibitors inhibit apoptosis of WC8 cells induced by Fas ligand. In animal models, they potently inhibit the progress of fulminant hepatitis and relieve alopecia caused by anticancer agents. Because of being highly safe, these apoptosis inhibitors are usable as beneficial drugs.
Abstract:
The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.
Abstract:
Cyclohexane derivatives of formula R1-A1-Z1-A2-R2 in which R1 and R2 in each case are H, an alkyl group with 1-10 C atoms, in which also one or two non-neighboring CH2 groups can be replaced by O atoms and/or -CO groups and/or -CO-O groups and/or -CH=CH groups, F, Cl, Br, CN or R3-A3-Z2-, A1 is -A-, A4-Zo-A- or -A-Zo-A4-, A is an unsubstituted cyclohexylene group, or a trans-1,4-cyclohexylene or 1,4-cyclohexenylene group substituted in 2nd, 3rd, 5th and/or 6th position once, or more than once by F and/or Cl and/or Br and/or CN and/or an alkyl group or a fluoridated alkyl group, each having 1-10 C atoms, in which also one or two non-neighboring CH2 groups can be replaced by O atoms and/or -CO groups and/or -CO-O groups, which cyclohexylene or cyclohexenylene group, as the case may be, also can be substituted in the 1st or 4th position, in which one or two CH2 groups are replaced by -CO-, or R1-A1- is a cyclohexyl group substituted in 3rd position by an alkyl group with 1-10 C atoms, in which one or two non-neighboring CH2 groups can be replaced by O atoms and/or -CO groups and/or -CO-O groups and/or -CH=CH- groups; or by -CN, in which cyclohexyl group also one or two non-neighboring CH2 groups can be substituted by -O- or -CO-, A2, A3 and A4 are in each case an unsubstituted 1,4-phenylene, or a 1,4-phenyl substituted by one or two F and/or Cl atoms and/or CH3 groups and/or CN groups, in which one or two CH groups can be replaced by N atoms and/or NO, 1,4 cyclohexylene, in which also one or two non-neighboring CH2 groups can be substituted by O atoms, 1,3-dithiane-2,5-diyl, piperidine-1,4-diyl, 1,4 bicyclo(2,2,2)-octylene-, decahydronaphtaline-2,6-diyl- or 1,2,3,4-tetrahydronaphthaline-2,6-diyl groups, or -A- Zo, Z1 and Z2 are in each case -CO-O-, -O-CO-, -CH2CH2-, -OCH2-, -CH2O-, -CH2CO-, COCH2-, -CH2CHCN-, -CHCNCH2-, or a simple link, and R3 is H, an alkyl group with 1-10 C atoms, in which also one or two non-neighboring CH2 groups can be substituted by O atoms and/or -CO-groups and/or -CO-O- groups and/or -CH=CH- groups, or signifies F, Cl, Br or CN, are suitable as components for liquid crystal phases.
Abstract:
This invention relates to a process for the production of quinone methide and more particularly to a method for process which optimizes the production of quinone methide, in particular 4-Benzylidene-2,6-di-te/t-butyl-cyclohexa-2,5- dienone, while limiting the production of by products or waste.